Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review

The document reviews the use of Janus kinase (JAK) inhibitors, such as baricitinib, tofacitinib, and ruxolitinib, in treating alopecia areata, an autoimmune disease causing hair loss. These inhibitors have shown promising results in several studies, with significant hair regrowth reported in a majority of patients. However, they may have adverse effects like increased risks of infection, malignancy, anemia, thrombocytopenia, and hyperlipidemia. The efficacy of topical JAK inhibitors is uncertain due to a lack of large-scale randomized controlled clinical trials. Biomarkers are being identified to predict treatment response, which could help in selecting appropriate treatment. However, these inhibitors only temporarily halt disease activity, with hair loss reported within weeks after discontinuation. As there are no curative treatments available, long-term JAK inhibitor therapy may be necessary to maintain hair regrowth. Future studies should focus on optimal maintenance dosage regimens and potential adverse effects of long-term treatment.